Actinogen Medical Ltd (ASX: ACW) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Actinogen Medical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$73.63 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.95 billion
Earnings per share
-0.007
Dividend per share
N/A
Year To Date Return
79.73%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Actinogen Medical Ltd (ASX: ACW)
Latest News
Share Gainers
Why Actinogen, Novonix, ResMed, & Zip shares are pushing higher
Share Gainers
Why the Actinogen (ASX:ACW) share price is rocketing 17% higher
Healthcare Shares
Here's why the Actinogen Medical (ASX: ACW) share price is up 20%
⏸️ ASX Shares
These 5 ASX shares are delivering the biggest gains in 2021
Share Gainers
Why is the Actinogen (ASX:ACW) share price up 414% in 3 months?
Healthcare Shares
Why is the Actinogen (ASX:ACW) share price falling 17% today?
Healthcare Shares
Actinogen (ASX:ACW) share price surges 23% today, 165% this year
Healthcare Shares
Actinogen Medical (ASX:ACW) share price jumps on patent news
Share Market News
Why Actinogen Medical shares climbed 466% on excitement over an Alzheimer's treatment
Share Fallers
Actinogen Medical share price crashes 67% lower on Alzheimer's study results
❮2
ACW ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Actinogen Medical Ltd
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
ACW Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 01 Nov 2024 | $0.03 | $0.00 | 0.00% | 2,646,344 | $0.03 | $0.03 | $0.02 |
| 31 Oct 2024 | $0.02 | $0.00 | 0.00% | 1,295,273 | $0.02 | $0.03 | $0.02 |
| 30 Oct 2024 | $0.03 | $0.00 | 0.00% | 1,991,179 | $0.03 | $0.03 | $0.02 |
| 29 Oct 2024 | $0.02 | $0.00 | 0.00% | 10,017,536 | $0.03 | $0.03 | $0.02 |
| 28 Oct 2024 | $0.03 | $0.00 | 0.00% | 4,961,444 | $0.03 | $0.03 | $0.03 |
| 25 Oct 2024 | $0.03 | $0.00 | 0.00% | 3,043,638 | $0.03 | $0.03 | $0.03 |
| 24 Oct 2024 | $0.03 | $0.00 | 0.00% | 2,259,751 | $0.03 | $0.03 | $0.03 |
| 23 Oct 2024 | $0.03 | $0.00 | 0.00% | 5,678,259 | $0.03 | $0.03 | $0.03 |
| 22 Oct 2024 | $0.03 | $0.00 | 0.00% | 4,922,649 | $0.03 | $0.03 | $0.03 |
| 21 Oct 2024 | $0.03 | $0.00 | 0.00% | 3,020,652 | $0.03 | $0.03 | $0.03 |
| 18 Oct 2024 | $0.03 | $0.00 | 0.00% | 8,316,825 | $0.03 | $0.03 | $0.03 |
| 17 Oct 2024 | $0.03 | $0.00 | 0.00% | 1,368,016 | $0.03 | $0.03 | $0.03 |
| 16 Oct 2024 | $0.03 | $0.00 | 0.00% | 1,745,130 | $0.03 | $0.03 | $0.03 |
| 15 Oct 2024 | $0.03 | $0.00 | 0.00% | 3,422,949 | $0.03 | $0.03 | $0.03 |
| 14 Oct 2024 | $0.03 | $0.00 | 0.00% | 4,741,829 | $0.03 | $0.03 | $0.03 |
| 11 Oct 2024 | $0.03 | $0.00 | 0.00% | 5,872,406 | $0.03 | $0.03 | $0.03 |
| 10 Oct 2024 | $0.03 | $0.00 | 0.00% | 14,115,712 | $0.03 | $0.03 | $0.03 |
| 09 Oct 2024 | $0.03 | $0.00 | 0.00% | 3,257,093 | $0.03 | $0.03 | $0.03 |
| 08 Oct 2024 | $0.03 | $0.00 | 0.00% | 18,891,332 | $0.03 | $0.03 | $0.03 |
| 07 Oct 2024 | $0.03 | $0.00 | 0.00% | 2,276,292 | $0.03 | $0.03 | $0.03 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Jun 2024 | George Morstyn | Issued | 374,213 | $10,852 |
Rights issue.
|
| 05 Jun 2024 | George Morstyn | Issued | 521,456 | $13,036 |
Rights issue.
|
| 05 Jun 2024 | George Morstyn | Issued | 226,969 | $5,674 |
Rights issue.
|
| 05 Jun 2024 | Malcolm McComas | Issued | 148,241 | $3,706 |
Rights issue. As per announcement on 07-06-2024
|
| 05 Jun 2024 | Malcolm McComas | Issued | 300,000 | $7,500 |
Rights issue. As per announcement on 07-06-2024
|
| 05 Jun 2024 | Malcolm McComas | Issued | 224,121 | $6,499 |
Rights issue.
|
| 05 Jun 2024 | Geoffrey Brooke | Issued | 589,232 | $17,087 |
Rights issue.
|
| 05 Jun 2024 | Geoffrey Brooke | Issued | 1,003,378 | $25,084 |
Rights issue.
|
| 05 Jun 2024 | Geoffrey Brooke | Issued | 175,085 | $4,377 |
Rights issue.
|
| 05 Jun 2024 | Steven Gourlay | Issued | 2,400,000 | $69,600 |
Rights issue.
|
| 05 Jun 2024 | Steven Gourlay | Issued | 1,285,120 | $32,128 |
Rights issue.
|
| 05 Jun 2024 | Steven Gourlay | Issued | 3,514,880 | $87,872 |
Rights issue.
|
| 05 Jun 2024 | Nicki Vasquez | Issued | 366,667 | $9,166 |
Rights issue.
|
| 05 Jun 2024 | Nicki Vasquez | Issued | 183,334 | $5,316 |
Rights issue.
|
| 04 Apr 2024 | Malcolm McComas | Expiry | 3,000,000 | $87,000 |
Options expired.
|
| 01 Dec 2023 | Geoffrey Brooke | Issued | 12,000,000 | $375,000 |
Issued under employee share plan.
|
| 01 Dec 2023 | George Morstyn | Issued | 4,500,000 | $140,625 |
Issued under employee share plan.
|
| 01 Dec 2023 | Steven Gourlay | Issued | 20,000,000 | $625,000 |
Issued under employee share plan.
|
| 01 Dec 2023 | Malcolm McComas | Issued | 4,500,000 | $140,625 |
Issued under employee share plan.
|
| 01 Dec 2023 | Nicki Vasquez | Issued | 5,500,000 | $171,875 |
Issued under employee share plan.
|
| 27 Nov 2023 | Geoffrey Brooke | Expiry | 4,900,000 | $112,700 |
Options expired.
|
| 27 Nov 2023 | George Morstyn | Expiry | 1,500,000 | $34,500 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr George Morstyn | Non-Executive Director | Dec 2017 |
-
|
| Mr Malcolm John McComas | Non-Executive Director | Apr 2019 |
-
|
| Dr Geoffrey E.D Brooke | Non-Executive ChairmanNon-Executive Director | Feb 2021 |
-
|
| Dr Steven Gourlay | Chief Executive OfficerManaging Director | Mar 2021 |
-
|
| Dr Nicki Vasquez | Non-Executive Director | Mar 2023 |
Dr Vasquez is an biopharmaceutical executive with more than 25 years of biopharmaceutical discovery research and development experience. Dr Vasquez is currently Chief Portfolio Strategy & Alliance Officer at Sutro Biopharma, a clinical stage oncology company in San Francisco Prior to joining Sutro, Dr Vasquez was Vice President of Program & Portfolio Management at StemCells, Inc., Earlier in her career Dr Vasquez worked at Elan Pharmaceuticals where she held positions of increasing responsibility in Alzheimers disease and autoimmune discovery research, to Vice President Research Operations & Program Management, and Vice President Development Program & Portfolio Management. Dr Vasquez received her post-doctoral training at Genentech.
|
| Mr Peter Webse | Company Secretary |
-
|
|
| Peter Webse | Company Secretary |
-
|
|
| Michael Roberts | Investor Relations |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 250,917,257 | 13.82% |
| Dr Steven Gourlay | 48,362,300 | 2.66% |
| Edinburgh Technology Fund Limited | 48,147,864 | 2.65% |
| JSC Wealth Management Pty Ltd | 44,655,962 | 2.46% |
| Citicorp Nominees Pty Limited | 38,237,380 | 2.11% |
| Tisia Nominees Pty Ltd <Henderson Family A/C> | 29,440,621 | 1.62% |
| Garnsworthy Pension Fund Pty Ltd <Garnsworthy Pension Fund A/C> | 22,000,000 | 1.21% |
| Mr James Murch & Mrs Catherine Murch <MINJAL Super Fund A/C> | 20,500,000 | 1.13% |
| Kaleidoscope Holdings Pty Ltd <Kaleidoscope Super A/C> | 20,346,473 | 1.12% |
| SG Gourlay Nominees Pty Ltd <SF Gourlay Family A/C> | 15,797,222 | 0.87% |
| Amber Court Nominees Pty Ltd <Min Min Light A/C> | 15,023,401 | 0.83% |
| Iral Pty Ltd <IRAL A/C> | 15,000,000 | 0.83% |
| Mrs Gillian Karen Nes & Mrs Ronald Nes <GIRO S/F A/C> | 15,000,000 | 0.83% |
| Big Eater Pty Ltd <Brigitte Smith Family A/C> | 12,999,659 | 0.72% |
| John Dahlsen Superannuation Fund Pty Ltd | 12,900,000 | 0.71% |
| HSBC Custody Nominees (Australia) Limited – A/C 2 | 12,461,934 | 0.69% |
| Rickenbacker Capital Investments Pty Ltd | 10,400,000 | 0.57% |
| Brazil Farming Pty Ltd | 10,069,970 | 0.55% |
| Van Am Marketing Pty Ltd | 10,000,854 | 0.55% |
| SVE Capital Pty Ltd <Strategic Vision Unit A/C> | 10 | 0.59% |
